David Gaiero
Directeur Financier/CFO chez CYTEIR THERAPEUTICS, INC.
Fortune : 308 197 $ au 31/03/2024
Profil
David Gaiero is currently the Chief Financial Officer & Treasurer at Cyteir Therapeutics, Inc. He previously worked as the Chief Financial & Accounting Officer at Wave Life Sciences Ltd.
from 2017 to 2020 and as the Vice President & Global Controller at OvaScience, Inc. from 2015 to 2017.
Mr. Gaiero completed his undergraduate degree at the University of Massachusetts.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 04/03/2024 | 102 391 ( 0,28% ) | 308 197 $ | 31/03/2024 |
Postes actifs de David Gaiero
| Sociétés | Poste | Début |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Directeur Financier/CFO | 01/12/2020 |
Anciens postes connus de David Gaiero
| Sociétés | Poste | Fin |
|---|---|---|
| WAVE LIFE SCIENCES LTD. | Directeur Financier/CFO | 04/12/2020 |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Comptroller/Controller/Auditor | 01/01/2017 |
Formation de David Gaiero
| University of Massachusetts | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| WAVE LIFE SCIENCES LTD. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
